Nanyang Biologics, supported by The9, to become publicly traded through $1.5B SPAC merger; stock prices rise
Merger Announcement: Nanyang Biologics, supported by The9 Limited, is set to merge with SPAC RF Acquisition Corp II, aiming for a public listing on Nasdaq under the ticker symbol "NYB" with a pre-transaction equity value of $1.5 billion.
Ownership and Control: Shareholders of NYB, including The9, will maintain majority ownership and board control by rolling over 100% of their equity, with the transaction expected to close in Q1 or Q2 of 2026.
Trade with 70% Backtested Accuracy
Analyst Views on RFAI
About RFAI
About the author
Nanyang Biologics, supported by The9, to become publicly traded through $1.5B SPAC merger; stock prices rise
Merger Announcement: Nanyang Biologics, supported by The9 Limited, is set to merge with SPAC RF Acquisition Corp II, aiming for a public listing on Nasdaq under the ticker symbol "NYB" with a pre-transaction equity value of $1.5 billion.
Ownership and Control: Shareholders of NYB, including The9, will maintain majority ownership and board control by rolling over 100% of their equity, with the transaction expected to close in Q1 or Q2 of 2026.
The9's Singapore Investee NYB Announce Plan to Go Nasdaq via US$1.5 Billion Business Combination with SPAC RF Acquisition Corp II
Proposed Business Combination: Nanyang Biologics Pte. Ltd. (NYB) has entered into a business combination agreement with RF Acquisition Corp II (RFAI), which will lead to NYB becoming a publicly listed company on Nasdaq, with an estimated pre-transaction equity value of $1.5 billion.
AI-Driven Drug Discovery Initiatives: NYB aims to enhance drug discovery through its AI platform and a partnership with Nvidia, HP, and Equinix to create the world's largest natural compound library, focusing on developing precision medicines for cancer and other health issues.
Nanyang Biologics, supported by The9, to become publicly traded through $1.5B SPAC merger; stock prices rise
Merger Announcement: Nanyang Biologics, supported by The9 Limited, is set to merge with SPAC RF Acquisition Corp II, aiming for a public listing on Nasdaq under the ticker symbol "NYB" with a pre-transaction equity value of $1.5 billion.
Ownership and Control: Shareholders of NYB, including The9, will maintain majority ownership and board control by rolling over 100% of their equity, with the transaction expected to close in Q1 or Q2 of 2026.
The9's Singapore Investee NYB Announce Plan to Go Nasdaq via US$1.5 Billion Business Combination with SPAC RF Acquisition Corp II
Proposed Business Combination: Nanyang Biologics Pte. Ltd. (NYB) has entered into a business combination agreement with RF Acquisition Corp II (RFAI), which will lead to NYB becoming a publicly listed company on Nasdaq, with an estimated pre-transaction equity value of $1.5 billion.
AI-Driven Drug Discovery Initiatives: NYB aims to enhance drug discovery through its AI platform and a partnership with Nvidia, HP, and Equinix to create the world's largest natural compound library, focusing on developing precision medicines for cancer and other health issues.
